|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|||
|
Rasagiline: Neurodegeneration, Neuroprotection, and Mitochondrial Permeability Transition |
Rasagilina: Neurodegeneración, Neuroprotección y Transición de la Permeabilidad Mitocondrial |
||
|
Rasagilina, molécula de propargil, miembros de la familia Bcl-2, proteinquinasa C, caspasa 3, células de neuroblastoma SHSY5Y |
SHSY5Y neuroblastoma cells, caspase-3, protein kinase C, Bcl-2 family members, propargyl moiety, rasagiline |
||
|
Youdim MBH, Bar Am O, Yogev-Falach M |
MBH Youdim, Department of Pharmacology, Technion-Faculty of Medicine Haifa Israel |
||
|
Teva Pharmaceutical Company, Haifa, Israel; National Parkinson Foundation; Stein Foundation. |
Los autores no manifiestan conflictos de interés |
||
|
Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute - Technion-Faculty of Medicine |
|||
|
ReSIIC editado en las
especialidades: |
|||
|
|
|
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
|